JP2014534265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534265A5 JP2014534265A5 JP2014543618A JP2014543618A JP2014534265A5 JP 2014534265 A5 JP2014534265 A5 JP 2014534265A5 JP 2014543618 A JP2014543618 A JP 2014543618A JP 2014543618 A JP2014543618 A JP 2014543618A JP 2014534265 A5 JP2014534265 A5 JP 2014534265A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- amino acid
- acid sequence
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563985P | 2011-11-28 | 2011-11-28 | |
| US61/563,985 | 2011-11-28 | ||
| PCT/US2012/066795 WO2013082116A1 (en) | 2011-11-28 | 2012-11-28 | Therapeutic agents comprising insulin amino acid sequences |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014534265A JP2014534265A (ja) | 2014-12-18 |
| JP2014534265A5 true JP2014534265A5 (enExample) | 2016-01-21 |
Family
ID=48536000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543618A Pending JP2014534265A (ja) | 2011-11-28 | 2012-11-28 | インスリンアミノ酸配列を含む治療薬 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20130150291A1 (enExample) |
| EP (1) | EP2785367A4 (enExample) |
| JP (1) | JP2014534265A (enExample) |
| KR (1) | KR20140103985A (enExample) |
| CN (1) | CN104080473A (enExample) |
| AU (1) | AU2012346058A1 (enExample) |
| BR (1) | BR112014012789A2 (enExample) |
| CA (1) | CA2856967A1 (enExample) |
| HK (1) | HK1202067A1 (enExample) |
| IL (1) | IL232781A0 (enExample) |
| MX (1) | MX2014006391A (enExample) |
| RU (1) | RU2014126244A (enExample) |
| SG (1) | SG11201402661TA (enExample) |
| WO (1) | WO2013082116A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| EP3412300A1 (en) | 2008-06-27 | 2018-12-12 | Duke University | Therapeutic agents comprising elastin-like peptides |
| EP2717902B1 (en) | 2011-06-06 | 2018-01-24 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
| US20150290328A1 (en) | 2012-11-20 | 2015-10-15 | Phasebio Pharmaceuticals, Inc. | Formulations of active agents for sustained release |
| JP2016505627A (ja) * | 2013-01-15 | 2016-02-25 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 治療剤、組成物、および血糖コントロールのための方法 |
| US11052132B2 (en) | 2014-05-08 | 2021-07-06 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
| WO2015178466A1 (ja) * | 2014-05-21 | 2015-11-26 | 味の素株式会社 | フィブロイン様タンパク質の製造法 |
| AU2015349743B2 (en) * | 2014-11-21 | 2021-06-10 | Immunoforge Co., Ltd. | ELP fusion proteins for controlled and sustained release |
| CA2976038A1 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
| TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| EP3124495A1 (en) * | 2015-07-31 | 2017-02-01 | Centre National de la Recherche Scientifique (C.N.R.S.) | Derivatives of elastin-like polypeptides and uses thereof |
| CA2994279A1 (en) | 2015-08-04 | 2017-02-09 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
| CN105061566A (zh) * | 2015-09-05 | 2015-11-18 | 苏州普罗达生物科技有限公司 | 拟胰岛素多肽及其应用 |
| WO2017052305A1 (en) * | 2015-09-24 | 2017-03-30 | Hanmi Pharm. Co., Ltd. | Method of insulin production |
| KR101815080B1 (ko) | 2015-11-03 | 2018-01-04 | 재단법인대구경북과학기술원 | 췌장소도세포 및 엘라스틴 유사 인공 세포외 기질을 포함하는 당뇨병 치료용 약학적 조성물 |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| SG11201805195YA (en) | 2016-03-02 | 2018-07-30 | Merz Pharma Gmbh & Co Kgaa | Composition comprising botulinum toxin |
| WO2017189860A1 (en) | 2016-04-27 | 2017-11-02 | The Regents Of The University Of California | Preparation of functional homocysteine residues in polypeptides and peptides |
| WO2017192449A1 (en) * | 2016-05-06 | 2017-11-09 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
| WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
| JP2020500150A (ja) * | 2016-09-23 | 2020-01-09 | デューク ユニバーシティ | 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド |
| US11220467B2 (en) | 2017-01-11 | 2022-01-11 | Recycle Track Systems, Inc. | Indoor food waste fermentation and recycling process |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| WO2018233813A1 (en) | 2017-06-20 | 2018-12-27 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
| US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
| EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| US12257308B2 (en) | 2018-04-30 | 2025-03-25 | Duke University | Stimuli-responsive PEG-like polymer-based drug delivery platform |
| US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
| CN111939244B (zh) | 2019-05-14 | 2024-08-06 | 阿莫生命科学有限公司 | 用于预防或治疗糖尿病并发症的药物组合物 |
| KR102456958B1 (ko) * | 2019-05-14 | 2022-10-21 | 강원대학교 산학협력단 | 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| US12435116B2 (en) | 2019-10-16 | 2025-10-07 | Clarence Hurt | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome |
| AU2020396647A1 (en) * | 2019-12-06 | 2022-07-07 | Ajinomoto Co., Inc. | Method for producing peptide having physiological activity, and peptide comprising short linker |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69826705T2 (de) * | 1997-11-12 | 2006-02-23 | Alza Corp., Palo Alto | Verfahren zur dermalen verabreichung von polypeptiden |
| US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US8334257B2 (en) * | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| BRPI0707796A2 (pt) * | 2006-02-15 | 2011-05-10 | Imclone Systems Inc | formulaÇço, e, mÉtodo de tratamento |
| CN101616685B (zh) * | 2006-03-06 | 2013-07-24 | 阿穆尼克斯运营公司 | 非结构化重组聚合物和其应用 |
| EP3412300A1 (en) * | 2008-06-27 | 2018-12-12 | Duke University | Therapeutic agents comprising elastin-like peptides |
| WO2010014689A1 (en) * | 2008-07-29 | 2010-02-04 | Phasebio Pharmaceuticals, Inc. | Pharmaceutical formulations comprising elastin-like proteins |
| PT2459171T (pt) * | 2009-07-31 | 2017-08-16 | Sanofi Aventis Deutschland | Composição de insulina de atuação longa |
| WO2011020091A1 (en) * | 2009-08-14 | 2011-02-17 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
-
2012
- 2012-11-28 HK HK15102642.1A patent/HK1202067A1/xx unknown
- 2012-11-28 WO PCT/US2012/066795 patent/WO2013082116A1/en not_active Ceased
- 2012-11-28 US US13/687,776 patent/US20130150291A1/en not_active Abandoned
- 2012-11-28 BR BR112014012789A patent/BR112014012789A2/pt not_active IP Right Cessation
- 2012-11-28 SG SG11201402661TA patent/SG11201402661TA/en unknown
- 2012-11-28 JP JP2014543618A patent/JP2014534265A/ja active Pending
- 2012-11-28 EP EP12852785.0A patent/EP2785367A4/en not_active Withdrawn
- 2012-11-28 RU RU2014126244A patent/RU2014126244A/ru not_active Application Discontinuation
- 2012-11-28 MX MX2014006391A patent/MX2014006391A/es unknown
- 2012-11-28 KR KR1020147017232A patent/KR20140103985A/ko not_active Withdrawn
- 2012-11-28 CN CN201280068260.1A patent/CN104080473A/zh active Pending
- 2012-11-28 CA CA2856967A patent/CA2856967A1/en not_active Abandoned
- 2012-11-28 AU AU2012346058A patent/AU2012346058A1/en not_active Abandoned
-
2014
- 2014-05-25 IL IL232781A patent/IL232781A0/en unknown
- 2014-06-13 US US14/304,617 patent/US20140364362A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534265A5 (enExample) | ||
| RU2014126244A (ru) | Лекарственные средства, содержащие аминокислотные последовательности инсулина | |
| CN102026666B (zh) | 促胰岛素肽缀合物制剂 | |
| JP2010031018A5 (enExample) | ||
| JP6084215B2 (ja) | ポリエチレングリコールまたはその誘導体でｐｅｇ化されたエキセンジン−４類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物 | |
| RU2434640C2 (ru) | Лечение метастатического рака молочной железы | |
| ES2614287T3 (es) | Lixisenatida como terapia adicional a la insulina basal en diabetes de tipo 2 | |
| CN102718858A (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| CN102643339B (zh) | 一种glp-1类似物、制备方法及其应用 | |
| ES2932498T3 (es) | Composiciones que comprenden el péptido WKDEAGKPLVK | |
| ES2723887T3 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| MY158627A (en) | Halogen-stabilized insulin | |
| JP2016516076A5 (enExample) | ||
| JP2014526441A5 (enExample) | ||
| TW200301694A (en) | Bicarbonate-based solutions for dialysis therapies | |
| UA95488C2 (ru) | Концентрированный раствор метотрексата для подкожного введения | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2019517542A5 (enExample) | ||
| ES2971959T3 (es) | Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua | |
| JP2017529326A5 (enExample) | ||
| JP2019527053A5 (enExample) | ||
| ES2743767T3 (es) | Agente para prevenir y/o tratar dolor neuropático periférico causado por un fármaco anticancerígeno | |
| JP2014506579A5 (enExample) | ||
| JP2020533302A (ja) | 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ | |
| JP2020502056A5 (enExample) |